10 of the 28 patients were originally given a 350mg dose, and then 5 of those 10 were upgraded to 525 mg. So I would expect that most of those 12 whose circulating tumor cells and CAMLs increased after receiving leronlimab were probably given a sub-optimal dose to begin with.

I hope that is the answer, anyway. There are also lots of individual health conditions and differences in the will to live which are hard to account for in a trial... so there is that as well. Fig 3 from the ESMO poster shows that one of the patients with increased CTCs/CAMLs lived for right around 2 years; much longer than would be expected.

To use a baseball reference--we are still in the first inning as far as studying leronlimab and ICI's in cancer. There's bound to be a few more curveballs to come our way, and I suspect most we will hit, while some we will miss. Batting 1.000 is probably unrealistic in such a tough cancer like TNBC... But 5 home runs out of 7 at-bats with leronlimab is a pretty great start!